EZH1

Histone-lysine N-methyltransferase EZH1

12,310 patent compounds predicted against EZH1, 10,219 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL2595084	0.73	15/20
SCHEMBL2591377	1.00	13/20
SCHEMBL2594776	0.87	13/20
SCHEMBL9284572	0.71	13/20
SCHEMBL2585411	0.68	13/20
SCHEMBL2592949	0.68	13/20
SCHEMBL2595147	0.67	13/20
SCHEMBL2594105	0.61	13/20
SCHEMBL2594669	0.86	12/20
SCHEMBL2592678	0.81	12/20
SCHEMBL2588380	0.81	12/20
SCHEMBL2592809	0.79	12/20
SCHEMBL2594078	0.79	12/20
SCHEMBL2591555	0.75	12/20
SCHEMBL2595606	0.75	12/20
SCHEMBL2588379	0.75	12/20
SCHEMBL2595231	0.91	11/20
SCHEMBL2588991	0.81	11/20
SCHEMBL2585424	0.80	11/20
SCHEMBL2593765	0.80	11/20

Germline variants in EZH1 on Sugi Variant → ClinVar classifications, population frequency, and predictor agreement (AlphaMissense, SaProt, REVEL) Full EZH1 gene report on Sugi Atlas → Gene function, pathways, protein structure, constraint & interactions

Clinical trials — most relevant to EZH1 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
Phase Ⅰ/Ⅱ Study of SHR2554 in Combination With SHR1701 in Patients With Advanced Solid Tumors and B-cell Lymphomas	PHASE1/PHASE2	UNKNOWN
Study of the Beach Regimen on Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)	PHASE2	ACTIVE_NOT_RECRUITING
Study of Front Line Pembrolizumab and Valemetostat in PD-L1 Positive, HPV-Negative Recurrent/Metastatic Squamous Cell Carcinoma (SCC) of the Head and Neck: The PANTHERAS	PHASE1/PHASE2	WITHDRAWN
Study of XNW5004 Tablet in Combination With KEYTRUDA® (Pembrolizumab) in Subjects With Advanced Solid Tumors Who Failed Standard Treatments (KEYNOTE F19)	PHASE1/PHASE2	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer	PHASE1/PHASE2	RECRUITING
Efficacy and Safety of the Valemetostat in Patients With Selected Solid Tumors.	PHASE2	RECRUITING
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Testing the Addition of the Anti-cancer Drug, Tazemetostat, to the Usual Treatment (Dabrafenib and Trametinib) for Metastatic Melanoma That Has Progressed on the Usual Treatment	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING
IDH1 (AG 120) Inhibitor in Patients With IDH1 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma	PHASE2	WITHDRAWN
Zandelisib + Tazemetostat in R/R Follicular Lymphoma	PHASE1/PHASE2	WITHDRAWN
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
A Study to Assess Efficacy and Safety of Oral Tazemetostat in Adult Participants With Relapsed/Refractory Follicular Lymphoma That Does Not Have an EZH2 Gain-of-function Genetic Mutation	PHASE2	WITHDRAWN
IDH2 (AG 221) Inhibitor in Patients With IDH2 Mutated Myelodysplastic Syndrome	PHASE2	ACTIVE_NOT_RECRUITING
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Tazemetostat and Palbociclib With CPX-351for R/R AML	PHASE1	RECRUITING
Study of ORIC-944 in Patients With Metastatic Prostate Cancer	PHASE1	RECRUITING
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
Study of Tazemetostat in Adults With Follicular Lymphoma Previously Treated With at Least Two Therapies	nan	WITHDRAWN
Mechanisms of Immune Deficiency	nan	UNKNOWN
Target of Suv420h1/2 in Hepatocytes	nan	RECRUITING
Studying The Role of Key Epigenetic Mediators in Breast Cancer Patients	nan	RECRUITING
Association of Colorectal Cancer With Nutrition, Diet, Obesity, Diabetes Mellitus, and Genetic Alterations in Taiwan	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
Prospective Study of Molecular Predictors of Survival in Myelodysplastic Syndromes	nan	COMPLETED
The Association of G9a Protein and Clinical Outcome of Patients With Vulvar Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a EZH1 binder may also engage these)

Protein	Name	Similarity
Q5RDS6	—	1.000	Q5RDS6 →
A7E2Z2	—	1.000	A7E2Z2 →
P70351	—	1.000	P70351 →
Q4V863	—	1.000	Q4V863 →
Q08BS4	—	1.000	Q08BS4 →
Q28D84	—	1.000	Q28D84 →
Q61188	—	1.000	Q61188 →
EZH2	Histone-lysine N-methyltransferase EZH2	1.000	landscape →
Q4R381	—	0.999	Q4R381 →
Q28Z18	—	0.998	Q28Z18 →
P42124	—	0.998	P42124 →
Q98SM3	—	0.998	Q98SM3 →
O65312	—	0.996	O65312 →
KMT5B	Histone-lysine N-methyltransferase KMT5B	0.996	landscape →
A6QQR4	—	0.996	A6QQR4 →
Q8C0I4	—	0.995	Q8C0I4 →
F4JZ68	—	0.995	F4JZ68 →
Q8WML3	—	0.994	Q8WML3 →
Q5SVQ0	—	0.994	Q5SVQ0 →
Q8W595	—	0.994	Q8W595 →
Q5TKR9	—	0.994	Q5TKR9 →
KAT6B	Histone acetyltransferase KAT6B	0.994	landscape →
Q8BZ21	—	0.994	Q8BZ21 →
Q32KD2	—	0.994	Q32KD2 →
G5EEU2	—	0.994	G5EEU2 →
DNMT1	DNA (cytosine-5)-methyltransferase 1	0.994	landscape →
Q5RJX8	—	0.994	Q5RJX8 →
Q08639	—	0.994	Q08639 →
Q6IV56	—	0.994	Q6IV56 →
Q9C813	—	0.994	Q9C813 →